Additionally, the study did not evaluate for differences between RET+ NSCLC and oncogenic subsets of NSCLC other than ALK+ or ROS1+ NSCLC (such as EGFR-mutant NSCLC, BRAF-mutant NSCLC, etc.). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.